MYOM2 and Miyoshi myopathy: Research on the correlation between proteasome load and degradative capacity on the sensitivity of MM cells toward bortezomib was conducted [87], suggesting that the levels of M-proteins and proteasome expression can be biomarkers for proteasome inhibitor sensitivity.